Recent Quotes (30 days)

You have no recent quotes
chg | %

Miraculins Inc  

(Public, CVE:MOM)   Watch this stock  
Find more results for MOM
0.250
-0.020 (-7.41%)
Sep 2 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.25 - 0.27
52 week 0.09 - 0.70
Open 0.27
Vol / Avg. 43,500.00/74,792.00
Mkt cap 5.06M
P/E     -
Div/yield     -
EPS -0.23
Shares 20.23M
Beta -1.15
Inst. own     -

Key stats and ratios

Q2 (May '14) 2013
Net profit margin -16069.33% -3985.29%
Operating margin -20943.33% -3422.64%
EBITD margin - -3162.79%
Return on average assets -75.63% -135.57%
Return on average equity - -
CDP Score - -

Address

6-1250 Waverley Street
WINNIPEG, MB R3T 6C6
Canada
+1-204-4531408 (Phone)
+1-204-4531546 (Fax)

Website links

Description

Miraculins Inc. (Miraculins) is a Canada-based medical diagnostic development company focused on acquiring and advancing non-invasive tests for unmet clinical needs. The Company�s PreVu Non-Invasive Skin Cholesterol Test (PreVu) test is a coronary artery disease (CAD) risk assessment technology that measures cholesterol levels in a patient�s skin non-invasively and without the need for fasting. The Company's two primary technology programs are in the areas of cardiovascular disease and maternal health. As of February 8, 2012, the Company�s preeclampsia program was being advanced in partnership with Alere, Inc., a diagnostic company. In August 2013, Miraculins Inc acquired all relevant assets, including intellectual property, licenses and regulatory approvals, inventories, data and marketing materials, relating to the SCOUT DS technology from VeraLight Inc.

Officers and directors

Harry Bloomfield Independent Chairman of the Board
Christopher Moreau President, Chief Executive Officer, Director
James F. Kinley CA Chief Financial Officer
Age: 35
James Mellon Independent Director
Age: 57
William Dwight Roberts Independent Director
Michael Stasiuk Independent Director